---
figid: PMC6293987__nihms-995765-f0001
figlink: /pmc/articles/PMC6293987/figure/F1/
number: F1
caption: 'Binding of growth factors and cytokines to a receptor tyrosine kinase (RTK)
  located on the cell membrane activates class I PI3K, which is a heterodimer of p85
  and a p110 isoform (p110α is illustrated here). The catalytic subunit of PI3K (p110α)
  phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2), generating phosphatidylinositol
  (3,4,5)-triphosphate (PIP3). PIP3 activates protein kinase B (Akt), which subsequently
  triggers mTOR (mechanistic target of rapamycin) activity. Therapeutic targets that
  inhibit various components of this signaling pathway include the following: p110α
  inhibitor (alpelisib/BYL719), pan PI3K inhibitors (buparlisib/BKM120, copanlisib/BAY-80–6946,
  PX-866, and SF1126), dual PI3K/mTOR inhibitor (BEZ-253), Akt inhibitor (MK-2206),
  and mTOR inhibitors (sirolimus/rapamycin, everolimus, and temsirolimus).'
pmcid: PMC6293987
papertitle: Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
reftext: Janice Cho, et al. Semin Radiat Oncol. 2018 Jan;28(1):2-11.
pmc_ranked_result_index: '25679'
pathway_score: 0.962768
filename: nihms-995765-f0001.jpg
figtitle: Components of the phosphoinositide 3-kinase (PI3K) signaling pathway and
  its associated therapeutic targets
year: '2018'
organisms:
- Homo sapiens
ndex: ff0998ef-de8f-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6293987__nihms-995765-f0001.html
  '@type': Dataset
  description: 'Binding of growth factors and cytokines to a receptor tyrosine kinase
    (RTK) located on the cell membrane activates class I PI3K, which is a heterodimer
    of p85 and a p110 isoform (p110α is illustrated here). The catalytic subunit of
    PI3K (p110α) phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2), generating
    phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 activates protein kinase
    B (Akt), which subsequently triggers mTOR (mechanistic target of rapamycin) activity.
    Therapeutic targets that inhibit various components of this signaling pathway
    include the following: p110α inhibitor (alpelisib/BYL719), pan PI3K inhibitors
    (buparlisib/BKM120, copanlisib/BAY-80–6946, PX-866, and SF1126), dual PI3K/mTOR
    inhibitor (BEZ-253), Akt inhibitor (MK-2206), and mTOR inhibitors (sirolimus/rapamycin,
    everolimus, and temsirolimus).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - AKT2
  - PIK3CB
  - PIK3R5
  - PIK3R4
  - PIK3CA
  - PIK3CD
  - PIK3CG
  - MTOR
  - AKT1
  - PIK3R3
  - PIK3R6
  - AKT3
  - MK-2206
  - BYL719
  - Sirolimus
  - rapamycin
  - Everolimus
  - Temsirolimus
  - BEZ-235
  - SF1126
genes:
- word: EGFR)
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
chemicals:
- word: MK-2206
  source: MESH
  identifier: C548887
- word: BYL719
  source: MESH
  identifier: C585539
- word: Sirolimus
  source: MESH
  identifier: D020123
- word: rapamycin
  source: MESH
  identifier: D020123
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: BEZ-235
  source: MESH
  identifier: C531198
- word: SF1126
  source: MESH
  identifier: C526549
diseases: []
figid_alias: PMC6293987__F1
redirect_from: /figures/PMC6293987__F1
figtype: Figure
---
